{"id":689805,"date":"2022-09-28T10:03:03","date_gmt":"2022-09-28T14:03:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/"},"modified":"2022-09-28T10:03:03","modified_gmt":"2022-09-28T14:03:03","slug":"iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/","title":{"rendered":"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation<\/b><\/p>\n<p class=\"bwalignc\"><i>IQVIA becomes first DCT program to demonstrate commitment to data protection in Europe<\/i><\/p>\n<p>RESEARCH TRIANGLE PARK, N.C.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nIQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation.\n<\/p>\n<p>\nTRUSTArc\u2019s third-party validation demonstrates that IQVIA\u2019s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials.\n<\/p>\n<p>\n\u201cAt IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,\u201d said Ronan Brown, SVP and head of Patient Centric Solutions &amp; Decentralized Trials. \u201cIQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.\u201d\n<\/p>\n<p>\nTRUSTArc maps it\u2019s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it\u2019s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development.\n<\/p>\n<p>\n\u201cAchieving a GDPR validation demonstrates IQVIA\u2019s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves,\u201d said Chris Babel, CEO, TRUSTArc. \u201cOrganizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.\u201d\n<\/p>\n<p>\nLearn more about the IQVIA <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iqvia.com%2Fsolutions%2Fresearch-and-development%2Fdecentralized-trials&amp;esheet=52926286&amp;newsitemid=20220928005056&amp;lan=en-US&amp;anchor=Decentralized+Clinical+Trial+platform+here&amp;index=1&amp;md5=40cb0bc2341fc5d34904da5b0de1312e\">Decentralized Clinical Trial platform here<\/a>.\n<\/p>\n<p><b>About IQVIA<br \/>\n<br \/><\/b>IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence\u2122 delivers powerful insights with speed and agility \u2014 enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries.\n<\/p>\n<p>\nIQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA\u2019s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iqvia.com&amp;esheet=52926286&amp;newsitemid=20220928005056&amp;lan=en-US&amp;anchor=www.iqvia.com&amp;index=2&amp;md5=d6adfb5fb0195b1be8bcf17bd5ce4be7\">www.iqvia.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20220928005056\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20220928005056\/en\/<\/a><\/span><\/p>\n<p>\nNick Childs, IQVIA Investor Relations (<a rel=\"nofollow\" href=\"mailto:nick.childs@iqvia.com\">nick.childs@iqvia.com<\/a>)<br \/>\n<br \/>+1.973.316.3828\n<\/p>\n<p>\nTrent Brown, IQVIA Media Relations (<a rel=\"nofollow\" href=\"mailto:trent.brown@iqvia.com\">trent.brown@iqvia.com<\/a>)<br \/>\n<br \/>+1.919.780.3221\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America North Carolina<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Technology Security Clinical Trials Practice Management Biotechnology Networks Managed Care Health Data Management<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220928005056\/en\/1582793\/3\/Website_Featured_JPG-IQVIA_Logo_-_Tricolor.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation IQVIA becomes first DCT program to demonstrate commitment to data protection in Europe RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc\u2019s third-party validation demonstrates that IQVIA\u2019s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. \u201cAt IQVIA, we are committed to delivering decentralized studies, we &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-689805","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation IQVIA becomes first DCT program to demonstrate commitment to data protection in Europe RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc\u2019s third-party validation demonstrates that IQVIA\u2019s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. \u201cAt IQVIA, we are committed to delivering decentralized studies, we &hellip; Continue reading &quot;IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T14:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation\",\"datePublished\":\"2022-09-28T14:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/\"},\"wordCount\":559,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/\",\"name\":\"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2022-09-28T14:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/","og_locale":"en_US","og_type":"article","og_title":"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation - Market Newsdesk","og_description":"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation IQVIA becomes first DCT program to demonstrate commitment to data protection in Europe RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc\u2019s third-party validation demonstrates that IQVIA\u2019s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. \u201cAt IQVIA, we are committed to delivering decentralized studies, we &hellip; Continue reading \"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-28T14:03:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation","datePublished":"2022-09-28T14:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/"},"wordCount":559,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/","name":"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2022-09-28T14:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220928005056r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-decentralized-clinical-trial-program-achieves-independent-gdpr-validation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=689805"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689805\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=689805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=689805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=689805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}